Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy

PHASE3CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

February 13, 2012

Primary Completion Date

July 20, 2021

Study Completion Date

July 20, 2021

Conditions
Duchenne Muscular DystrophyCardiomyopathyHeart Failure
Interventions
DRUG

Nebivolol

A 1.25mg-test dose will be administrated to assess the treatment tolerance before randomization. A forced titration of nebivolol will be performed with 2 weeks periods. Full dose of nebivolol is 5mg/day (7.5mg/day for patients whose weight is\>60kg)

DRUG

Placebo

A 1.25mg-test dose of nebivolol will be administrated to assess the treatment tolerance before randomization. A forced titration of placebo will be performed with 2 weeks periods. Full dose of placebo is 5mg/day (7.5mg/day for patients whose weight is\>60kg)

Trial Locations (1)

75012

Armand Trousseau Hospital, Paris

All Listed Sponsors
collaborator

Association Française contre les Myopathies (AFM), Paris

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT01648634 - Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter